<DOC>
	<DOCNO>NCT02847624</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness tolvaptan patient autosomal dominant polycystic kidney disease ( ADPKD ) real world clinical setting Japan .</brief_summary>
	<brief_title>Post-Marketing Surveillance Study Tolvaptan Patients With ADPKD</brief_title>
	<detailed_description />
	<mesh_term>Polycystic Kidney Diseases</mesh_term>
	<mesh_term>Polycystic Kidney , Autosomal Dominant</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>diagnose ADPKD total kidney volume 750</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>